• January 7, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

    Read the full article

    Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of… Continue Reading >

    Read the full Press Release
  • September 9, 2015

    Article Spotlight

    The Site of Intracellular Metabolism May Be a Relevant Drug Target in Dry AMD

    Read the full article

    In the May/June cover story of Retina Today, Scott W. Cousins, MD, offers insights into how our investigational mitochondrial targeted drug Ocuvia (MTP-131) may help treat age-related macular degeneration (AMD). AMD accounts for 54% of all blindness in Americans of European ancestry and 5% globally. It is the most common cause of blindness in the… Continue Reading >

    Read the full Article
  • June 25, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

    Read the full article

    Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial Science… Continue Reading >

    Read the full Press Release
  • April 27, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

    Read the full article

    Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic… Continue Reading >

    Read the full Press Release

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of… Continue Reading >

Stealth BioTherapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference

Corporate Presentation on Wednesday, July 8th, 2015 at 9:30 AM ET BOSTON – July 7, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced its Chief Executive Officer, Travis Wilson, will present a corporate overview and development update at Cantor Fitzgerald’s Inaugural Healthcare Conference in New York… Continue Reading >

Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial Science… Continue Reading >

Stealth BioTherapeutics Presents at 2015 United Mitochondrial Disease Foundation National Symposium

Orphan mitochondrial disease program highlighted during annual meeting Boston, MA – June 22, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, provided a development update for its investigational drugs, Bendavia and Ocuvia, and announced future clinical plans for its orphan mitochondrial disease program at the 2015 United Mitochondrial… Continue Reading >